Every discharge generates a record: who left the hospital, when, what happened next, and whether a real clinical encounter actually validated a diagnosis identified at that visit. That record has always mattered for revenue and quality performance, but seamless enhancements may also be needed to ensure audit compliance.
Real-time ADT signals were built to solve a timing problem: catching a discharge the moment it occurs, rather than weeks later, when claims data finally arrives. Roughly 80% of Transitional Care Management (TCM) windows are missed due to delayed data and manual processes, and undetected network leakage costs health systems and plans an estimated $500 million annually. But the same ADT-triggered workflow that closes those gaps can also serve as evidence of outreach for quality performance and audit needs.
The two biggest challenges facing risk adjustment today, revenue leakage and audit defensibility, are usually treated as separate conversations when they're not. A workflow that detects a discharge, triggers outreach within hours, schedules a follow-up, and closes HCC and quality gaps during that transition visit produces exactly the kind of encounter-backed documentation that holds up under scrutiny. It's the difference between a diagnosis with a real service event behind it and one that exists only on paper.
That distinction is exactly what regulators have been focused on. The Office of the Inspector General (OIG) found that diagnoses reported only on health risk assessments, or through HRA-linked chart reviews with no other service record behind them, drove an estimated $7.5 billion in Medicare Advantage risk-adjusted payments in 2023. When there's no follow-up visit, procedure, test, or supply tied to a diagnosis, OIG has raised a direct concern: either the diagnosis is inaccurate, and the payment is improper, or the enrollee never received the care implied by the diagnosis.
A related finding reinforces the same concern. OIG found that Medicare Advantage organizations used chart reviews to add diagnoses far more often than to remove them, with over 99% of chart reviews in one study adding diagnoses rather than deleting them. Unlinked chart review records alone were tied to an estimated $2.7 billion in potential overpayments in 2017. CMS has already begun acting on this pattern. As part of the CY 2027 Advance Notice, CMS proposed excluding diagnoses sourced from unlinked chart reviews from risk-adjusted payments altogether, a meaningful shift given that nearly 58% of Medicare Advantage contracts submitted unlinked chart review diagnoses in 2022.
The audit pressure behind all of this hasn't gone away, even though one piece of it is temporarily on hold. Extrapolation, the mechanism that would allow CMS to apply a sampled audit error rate across the entire contract population, is not currently in force. A federal court vacated the 2023 RADV final rule, which permitted extrapolation, on procedural grounds in September 2025, and CMS appealed in November 2025. Audit activity itself hasn't slowed. CMS is pursuing an aggressive strategy to clear the PY2018 through PY2024 backlog, and extrapolation exposure is widely expected to return through new rulemaking or a successful appeal. When it does, a small sampled error rate gets multiplied across an entire contract. A 5% error rate on a $1 billion contract becomes a $50 million recovery.
That's why the documentation behind each diagnosis, not just the diagnosis itself, is what will matter most going forward. A transition-linked record doesn't make a diagnosis audit-proof; RADV still validates against the medical record itself, and the diagnosis still needs a qualified provider's documentation at the required specificity. But it does provide corroboration with a real, timed clinical event standing behind the code, rather than a diagnosis floating on its own.
As audit activity accelerates and extrapolation exposure looms, the organizations best positioned won't be the ones capturing the most diagnoses. They'll be the ones who can show, diagnosis by diagnosis, exactly what clinical event supports it.
Have questions about how this applies to your program? Connect with Bamboo Health today to discuss more about what this could look like for your organization.